EARLY CANCER DETECTION TEST FOR LUNG (EarlyCDT-Lung)

• Main Authors: Syful Azlie Md Fuzi (Author), Erni Zurina Romli (Author), Wai, Lee Sit (Author)
• Corporate Author: KEMENTERIAN KESIHATAN MALAYSIA
• Format: Book
• Language: English
• Published: Putrajaya Malaysian Health Technology Assessment Section (MaHTAS) 2022
• Series: Health Technology Assessment Report
• Subjects: Lung Neoplasms
• Online Access: Click Here to View Status and Holdings.
• Item Description: This HTA report was endorsed in HTA & CPG Council Meeting 1/2022 (26 June 2022).
• Physical Description: xiv, 51 pages illustrations 29 cm
• Bibliography: Includes bibliographical references
• ISBN: 9789672887379

Most patients with lung cancer are diagnosed when they present with symptoms, at advanced stage disease, and curative treatment is no longer an option. An effective screening test has long been desired for early detection with the goal of reducing mortality from lung cancer. While low-dose computed tomography (LDCT) screening has shown promising result in the detection of early disease and has now been broadly documented to have the potential to reduce lung cancer mortality, it comes with risks of radiation-induced cancer, false-positive test results, unnecessary follow-up testing and increased financial costs, as well as over diagnosis. Currently, there has been a shift in the emphasis of biomarker using blood specimens as it is readily available through minimally invasive procedures and their measurements can be easily standardized. Following this, a commercially available assay, the EarlyCDT-Lung that measures autoantibodies to tumour associated antigens (TAAs) for the detection of lung cancer has been developed. Despite the magnitude of lung cancer cases been reported in Malaysia, there is no national lung cancer screening programme established yet. This review is timely to address the need for early detection of lung cancer in facilitating more effective non-invasive cancer control approaches in the country. Therefore, the purpose of this Health Technology Assessment (HTA) is to evaluate whether EarlyCDT-Lung would be effective, safe, and cost-effective as a screening tool for early lung cancer detection among high-risk group in the management of lung cancer in Malaysia. This assessment was requested by a Senior Consultant Pulmonologist from Serdang Hospital